5-fluorouracil / TrxR Cancer Research Results

5-FU, 5-fluorouracil: Click to Expand ⟱

Features:

5-FU is a chemotherapy medication used to treat various types of cancer, including colorectal, breast, stomach, and pancreatic cancer. It belongs to a class of drugs known as antimetabolites, which work by interfering with the growth and replication of cancer cells.
Mechanisms:
- functionally irreversibly inhibits Thymidylate Synthase (TS), thereby depleting the deoxythymidine monophosphate (dTMP) pool required for DNA synthesis. The resulting “thymineless death” prevents DNA replication and repair, particularly affecting rapidly proliferating tumor cells.

5-FU is a cornerstone in chemotherapy with a dual mechanism of action—primarily inhibiting thymidylate synthase (leading to disruption of DNA synthesis) and interfering with RNA processing by misincorporation. Its metabolism via activation (OPRT) and degradation (DPD) plays a crucial role in both its effectiveness and toxicity. Clinically, 5-FU is extensively used in treating a variety of cancers, most notably colorectal cancer, and remains a mainstay in multi-agent chemotherapeutic regimens due to its proven efficacy across diverse cancer types.

5-FU is one of the most common chemotherapeutic agents worldwide, particularly noted in gastrointestinal (GI) cancers.

Rank	Pathway / Axis	Cancer / Tumor Context	Normal Tissue Context	TSF	Primary Effect	Notes / Interpretation
1	Thymidylate synthase (TS) inhibition → dTMP depletion	dTMP ↓ → DNA synthesis ↓ → replication stress ↑	Also affects normal proliferating tissues (marrow, GI mucosa)	P, R	Core cytotoxic mechanism	5-FU is converted to FdUMP, which forms a ternary complex with TS and folate, blocking thymidylate production (“thymineless death”).
2	RNA misincorporation (FUTP incorporation)	RNA processing/translation defects ↑	Contributes to mucositis and systemic toxicity	P, R	Transcription/translation disruption	RNA effects are a major contributor to cytotoxicity, particularly with bolus dosing.
3	DNA misincorporation (FdUTP incorporation)	DNA damage signaling ↑; apoptosis ↑ (context)	DDR activation in normal tissues contributes to toxicity	R, G	Genome instability	Misincorporation triggers mismatch repair and DNA damage responses.
4	S-phase specificity (cell-cycle dependence)	Greater killing in actively cycling/S-phase cells	Bone marrow & GI epithelium vulnerability ↑	R, G	Cell-cycle–linked cytotoxicity	Antimetabolite activity is strongest in proliferating cells.
5	Folate modulation (leucovorin synergy)	TS inhibition ↑ when combined with leucovorin	—	R	Mechanism amplification	Leucovorin stabilizes the FdUMP–TS–folate complex, enhancing cytotoxicity.
6	Myelosuppression	—	Neutropenia/anemia risk ↑	R, G	Dose-limiting toxicity	Expected on-target effect in rapidly dividing marrow progenitors.
7	Gastrointestinal toxicity (mucositis/diarrhea)	—	GI epithelial injury ↑	R, G	Dose-limiting toxicity	Reflects RNA/DNA effects in rapidly renewing GI mucosa.
8	Cardiotoxicity (vasospasm; rare cardiomyopathy)	—	Chest pain/ischemia risk ↑ (rare but important)	R	Serious adverse effect	Coronary vasospasm is the most recognized mechanism; monitoring required in symptomatic patients.
9	DPD metabolism (DPYD enzyme)	Severe toxicity risk ↑ if DPD deficient	—	—	Pharmacogenetic constraint	Dihydropyrimidine dehydrogenase (DPD) metabolizes 5-FU; deficiency can cause life-threatening toxicity. Pre-treatment DPYD testing is increasingly recommended.
10	Infusion vs bolus pharmacodynamics	Continuous infusion → more TS-driven DNA effect	Bolus → more RNA-mediated toxicity	P, R, G	Dosing-dependent mechanism balance	Administration schedule alters relative DNA vs RNA contribution and toxicity profile.

Time-Scale Flag (TSF): P / R / G

P: 0–30 min (metabolic activation begins rapidly)
R: 30 min–3 hr (TS inhibition, RNA/DNA incorporation, DDR activation)
G: >3 hr (cell-cycle arrest, apoptosis, tissue-level toxicities)

TrxR, Thioredoxin Reductase: Click to Expand ⟱

Source:

Type:

TrxR is an enzyme that reduces Trx, allowing it to perform its reducing functions. It has been shown to have a role in cancer cell metabolism and survival.
TrxR is overexpressed in various types of cancer, including breast, lung, colon, and prostate cancer.

- Part of the thioredoxin system, which regulates reactive oxygen species (ROS).
- TrxR is a major antioxidant systems that maintains the intracellular redox homeostasis.
- Inhibition causes an increase in ROS.
- TrxR is often upregulated in cancer cells to help manage increased oxidative stress, it is seen as a potential therapeutic target. Inhibiting TrxR may result in increased ROS in cancer cells, pushing them toward apoptosis.
- TrxR is a selenoprotein—meaning it incorporates the trace element selenium in the form of the amino acid selenocysteine.

TrxR inhibitors:
-Piperlongumine
-Withania somnifera (Ashwagandha)
-Parthenolide
-EGCG
-Curcumin
-Myricetin
-Gambogic Acid

Scientific Papers found: Click to Expand⟱

1952-

PL,

5-FU,

Piperlongumine induces ROS accumulation to reverse resistance of 5-FU in human colorectal cancer via targeting TrxR

in-vivo,

CRC,

HCT8

10uM

mice

ROS↑, TrxR↓, eff↑, p‑Akt↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

ROS↑, 1, TrxR↓, 1,

Cell Death ⓘ

p‑Akt↓, 1,

Drug Metabolism & Resistance ⓘ

eff↑, 1,
Total Targets: 4

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: TrxR, Thioredoxin Reductase

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells